She explains how a lack of established risk factors in the European Union is hampering trial design and claim submission, with learnings coming on a case-by-case basis as European Food Safety Authority opinions are issued.
“There is a lot of frustration,” she said. “The industry have been told their data is not good enough ... they are trying to invest in better clinical studies but there is this uncertainty about what they should be measuring...”